SCHEMBL11949010

SCHEMBL11949010

CCN(CC)c1cc2[nH]c(-c3ccc(C)cc3)nc2cc1NC(=O)c1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 1/20 0.55
▸ HDAC6 Q9UBN7 5/20 0.54
▸ MMP2 P08253 7/20 0.52
▸ MMP9 P14780 7/20 0.52
▸ MMP8 P22894 7/20 0.52
▸ MMP13 P45452 7/20 0.52
▸ HPSE Q9Y251 3/20 0.51
▸ CHEK2 O96017 2/20 0.50
▸ HDAC3 O15379 2/20 0.48
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC8 Q9BY41 2/20 0.48
▸ EGFR P00533 1/20 0.48
▸ HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11948988 0.95 MMP2 (0.56) SIRT2HDAC6MMP2MMP9MMP8
SCHEMBL11949042 0.91 HDAC6 (0.53) SIRT2HDAC6MMP2MMP9MMP8
SCHEMBL11949007 0.91 MMP2 (0.58) SIRT2HDAC6MMP2MMP9MMP8
SCHEMBL11949018 0.90 HDAC6 (0.59) SIRT2HDAC6MMP2MMP9MMP8
SCHEMBL11949009 0.90 MMP2 (0.52) HDAC6MMP2MMP9MMP8MMP13
SCHEMBL3104076 0.90 MMP2 (0.59) HDAC6MMP2MMP9MMP8MMP13
SCHEMBL11949012 0.90 MMP2 (0.64) HDAC6MMP2MMP9MMP8MMP13
SCHEMBL11949024 0.90 PRSS12 (0.56) SIRT2HDAC6MMP2MMP9MMP8
SCHEMBL11949033 0.89 PRSS12 (0.57) HDAC6MMP2MMP9MMP8MMP13
SCHEMBL11949039 0.86 NR4A2 (0.55) HDAC6MMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232410-B2 Benzimidazoles and pharmaceutical compositions thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2012-07-31 — — US disclosed
US-8232410-B2 Benzimidazoles and pharmaceutical compositions thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2012-07-31 — — US disclosed
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2010-10-07 — — US disclosed
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2010-10-07 — — US disclosed
WO-2008130669-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2008-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF TBCD, TBC1D5, CFTR SIRT2 1501/4885HDAC6 47/4885MMP2 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback